Incyte Ceases Trial of Metastatic Colorectal Cancer Candidate

Biopharmaceutical company Incyte has ceased its Phase 2 study of its metastatic colorectal cancer and high C-reactive protein candidate.

The trial — which studied Jakafi in combination with regorafenib compared with placebo — failed to show a sufficient level of efficacy in the high CRP subgroup to warrant continuation, the Wilmington, Del.-based drugmaker said.

Jakafi is also in a late-stage trial for the treatment of pancreatic cancer.